Lilly downsizes Va. plant

Two years behind schedule, Eli Lilly says it will cut plans for a new manufacturing facility in Virginia and hire only half of the 700 workers it originally promised when lining up millions of dollars in public support for the project. Analysts say that sagging demand for insulin products helped inspire the cutbacks. Public officials say that the project is still worth the more than $7 million in economic incentives offered by the county and state.

- read this article from The Washington Post for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.